GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Motus GI Holdings Inc (OTCPK:MOTS) » Definitions » Debt-to-EBITDA

Motus GI Holdings (Motus GI Holdings) Debt-to-EBITDA : -0.32 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Motus GI Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Motus GI Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.75 Mil. Motus GI Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.69 Mil. Motus GI Holdings's annualized EBITDA for the quarter that ended in Mar. 2024 was $-7.53 Mil. Motus GI Holdings's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.32.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Motus GI Holdings's Debt-to-EBITDA or its related term are showing as below:

MOTS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.8   Med: -0.58   Max: -0.22
Current: -0.26

During the past 9 years, the highest Debt-to-EBITDA Ratio of Motus GI Holdings was -0.22. The lowest was -0.80. And the median was -0.58.

MOTS's Debt-to-EBITDA is ranked worse than
100% of 437 companies
in the Medical Devices & Instruments industry
Industry Median: 1.25 vs MOTS: -0.26

Motus GI Holdings Debt-to-EBITDA Historical Data

The historical data trend for Motus GI Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Motus GI Holdings Debt-to-EBITDA Chart

Motus GI Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -0.38 -0.48 -0.69 -0.69 -0.22

Motus GI Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.68 -0.98 -1.03 -0.24 -0.32

Competitive Comparison of Motus GI Holdings's Debt-to-EBITDA

For the Medical Devices subindustry, Motus GI Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Motus GI Holdings's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Motus GI Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Motus GI Holdings's Debt-to-EBITDA falls into.



Motus GI Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Motus GI Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.202 + 1.266) / -11.429
=-0.22

Motus GI Holdings's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.748 + 0.69) / -7.532
=-0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Motus GI Holdings  (OTCPK:MOTS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Motus GI Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Motus GI Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Motus GI Holdings (Motus GI Holdings) Business Description

Traded in Other Exchanges
N/A
Address
1301 East Broward Boulevard, 3rd Floor, Fort Lauderdale, FL, USA, 33301
Motus GI Holdings Inc is a medical technology company dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the "FDA") to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal ("GI") endoscopy procedures. The Pure-Vu System is also CE marked in the European Economic Area (EEA) for use in colonoscopy.
Executives
Orchestra Biomed Holdings, Inc. 10 percent owner 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Scott Durbin director PO BOX 376, ANN ARBOR MI 48106
Elad Amor officer: Chief Accounting Officer MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FORT LAUDERDALE FL 33301
Ravit Ram officer: Chief Financial Officer MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FORT LAUDERDALE FL 33301
Timothy P. Moran director, officer: Chief Executive Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Andrew Lawrence Taylor officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Mark Pomeranz director, officer: President and COO C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Sonja Nelson director C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Oracle Partners Lp other: * See Remarks 200 GREENWICH AVE, 3RD FL, GREENWICH CT 06830
Larry N Feinberg other: * See Remarks C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Darren Sherman director C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
David P Hochman director, other: Chairman of the Board 15 WESTON HILL RD., RIVERSIDE CT 06878
Nussbaum Samuel R Md director WELLPOINT, INC, 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Shervin J Korangy director 850 PARK AVENUE, APT. 12B, NEW YORK NY 10075

Motus GI Holdings (Motus GI Holdings) Headlines